TY - JOUR
T1 - Advanced siRNA delivery in combating hepatitis B virus
T2 - mechanistic insights and recent updates
AU - Nguyen, Linh
AU - Nguyen, Tiep Tien
AU - Kim, Ju Yeon
AU - Jeong, Jee Heon
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk of liver carcinoma, several obstacles still hinder their effectiveness. These include viral resistance, prolonged treatment duration, and low efficacy in clearing viral antigens. To address these challenges in current HBV treatment, numerous approaches have been developed with remarkable success. Among these strategies, small-interfering RNA (siRNA) stands out as one of the most promising therapies for hepatitis B. However, naked siRNAs are vulnerable to enzymatic digestion, easily eliminated by renal filtration, and unable to cross the cell membrane due to their large, anionic structure. Therefore, effective delivery systems are required to protect siRNAs and maintain their functionality. In this review, we have discussed the promises of siRNA therapy in treating HBV, milestones in their delivery systems, and products that have entered clinical trials. Finally, we have outlined the future perspectives of siRNA-based therapy for HBV treatment. Graphical Abstract: (Figure presented.)
AB - Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk of liver carcinoma, several obstacles still hinder their effectiveness. These include viral resistance, prolonged treatment duration, and low efficacy in clearing viral antigens. To address these challenges in current HBV treatment, numerous approaches have been developed with remarkable success. Among these strategies, small-interfering RNA (siRNA) stands out as one of the most promising therapies for hepatitis B. However, naked siRNAs are vulnerable to enzymatic digestion, easily eliminated by renal filtration, and unable to cross the cell membrane due to their large, anionic structure. Therefore, effective delivery systems are required to protect siRNAs and maintain their functionality. In this review, we have discussed the promises of siRNA therapy in treating HBV, milestones in their delivery systems, and products that have entered clinical trials. Finally, we have outlined the future perspectives of siRNA-based therapy for HBV treatment. Graphical Abstract: (Figure presented.)
KW - Conjugation
KW - Delivery system
KW - Hepatitis B
KW - Lipid
KW - siRNA
UR - https://www.scopus.com/pages/publications/85211169917
U2 - 10.1186/s12951-024-03004-3
DO - 10.1186/s12951-024-03004-3
M3 - Review article
C2 - 39616384
AN - SCOPUS:85211169917
SN - 1477-3155
VL - 22
JO - Journal of Nanobiotechnology
JF - Journal of Nanobiotechnology
IS - 1
M1 - 745
ER -
